



























FY20 FINANCIAL HIGHLIGHTS



FY20 results were driven by the strong performance of **Bubs® Infant Formula** in all retail channels and regions.

\$62m
Group Gross Revenue¹

+32%

Group Gross Revenue¹ pcp

55%

Infant Formula Share Group Gross Revenue¹

+69%

Infant Formula Gross Revenue¹ growth pcp +32%

Direct sales to China growth pcp

5_x

Export sales growth pcp to emerging markets outside of China

\$26m

Cash reserves as at 30 June 2020

¹ Gross revenue is a non-IFRS measure. Non IFRS measures have not been subject to audit or review. Gross revenue represents the revenue recognised without rebates and marketing contribution.



FY20 GROUP FINANCIAL PERFORMANCE

Strong FY growth across core products in all regions.



GROUP GROSS REVENUE


Continued strong growth year on year.


REGIONAL CHANNEL MIX


Increasing market diversification.

BALANCED PRODUCT MIX

Optimising portfolio mix to maximise profitability.










UNDERPINNED BY STRONG CHINA DEMAND

China remains catalyst for global growth.



TOTAL CHINA DIRECT EXPORT GROWTH



- Growth driven by demand for Bubs® Goat Infant Formula portfolio.
- Supported by expansion into Mother & Baby Stores General Trade with China Label products.
- Scale in China provides platform for global expansion.





WE ARE NOW ENTERING THE THIRD PHASE OF BUBS® JOURNEY

Could have only been reached after period of gaining supply chain expertise and scale as a foundation for rapid global expansion built on brand trust, invaluable knowledge and intellectual property.



PHASE 1 CREATION

- Creation of Bubs® brand.
- Built authentic brand proposition.
- Gained trust and credentials.
- Grounded in Australian Provenance.

PHASE 2 FOUNDATION

- Built core competencies in vertical supply chain integration and secured goat dairy supply agreements.
- Established strategic partnerships with global retail giants.
- Gained valuable manufacturing assets, providing flexibility, deep technical and manufacturing know-how.

PHASE 3 GLOBAL EXPANSION

- Rapid expansion and replication of unique value proposition across multiple regions to deliver improved gross margin and profitability.
- Enter new adjacent high margin categories with emerging innovation.

2025



TRADITIONAL

SPACE FOR:


Ingredient &

manufacturing

led businesses.

OUR UNIQUE VALUE PROPOSITION

360° integrated business model, combining the best of an ingredient and manufacturing business, together with a brand-led and consumer focused portfolio driven business.




(



SPECIALIST LEADER IN AUSTRALIAN GOAT DAIRY

As Australia's largest goat dairy producer, we have now optimised the highest and best use of an exclusive milk source and gained valuable specialist dairy competencies.





ONE BRAND, MULTIPLE FEEDING OCCASIONS

Bubs® caters for all feeding occasions throughout a child's development. Our comprehensive portfolio provides a unique advantage to extend consumer lifecycle and increase basket size with single customer base and brand message.





DRIVING PUSH AND PULL CHINA CHANNEL STRATEGIES

Building momentum across China's complex ecosystem, pinpointing the most lucrative channel tiers and demographics, ensuring all paths lead to Bubs[®].



Q1 FY21: CHINA & INFANT FORMULA GROWTH

We remain true to our core strategy for sustainable profitable long-term growth.




DIRECT CHINA EXPORTS

BUBS® GOAT MILK FORMULA

+76% pcp


Significant export growth for Bubs® Infant Formula into China.



BUBS® INFANT FORMULA SALES ACROSS ALL CHANNELS


+9% pcp





-
- AustraliaChina
- Other International

BALANCED PRODUCT MIX



Q1FY20

- Infant formula
- Organic baby food
- Vitamins & Supplements
- Adult goat milk powder
- Fresh goat dairy
- Canning services

EXPORT SALES FOR INFANT FORMULA OUTSIDE OF CHINA

+6% pcp



With total sales to international markets outside of China now representing 8% of Q1 FY21 gross revenue.






ACCELERATING CHINA DEMAND ON CBEC

Demonstrating CBEC channel shift & continued strength of brand connection with our end China consumers, as well as positive outcome from our China strategic partnerships with Alibaba and Beingmate. Chinese consumer offtake demand remains strong.





*Source: Alibaba, total Tier 1 Platforms Bubs Infant Formula sales. ^Source: Alibaba, Tmall Global Sales Data as at 30 September 2020.



BUBS HOLDS 12% GOAT INFANT FORMULA MARKET SHARE ON TMALL GLOBAL^

+100% market share growth pcp.

No.1

Goat Brand on JD.com**



MILESTONE ACHIEVEMENT

Ahead of China's top selling Goat infant Nutrition Brand.

^{**}Source: JDI last 30 days total platform sales as at 8 October 2020.



OFFICIAL TMALL GLOBAL BUBS® 11.11 RESULTS +174% pcp.

Record results surpassing the previous year's total in first hour of Double 11 sales. Bubs® Goat ranked number 3 imported goat brand across Tmall Global and #1 Australian Goat brand in Tmall.²

Tmall Global (CBEC)¹ 11.11 Event Official ranking.



T-MALL Global Goat IMF Ranking



Tmall (General Trade and CBEC)² 11.11 event official ranking.





- #3 Imported goat brand across Tmall Global¹.
- #1 Australian Goat Milk brand in Tmall² (General Trade & CBFC) for official 11.11 sales results.
- #1 Australian Goat Milk brand in Tmall Global¹ (CBFC) for official 11.11 sales results.
- #3 CBEC imported Goat IMF brand on Kaola³ official 11.11 results, behind our two largest international competitors.
- Bubs® Tmall flagship store surpassed prior year's total Double 11 sales in first hour.
- Bubs sales on Tmall Global increased by 174% vs. Double 11 last year¹.
- Bubs® Goat official Double 11 event ranking on JD also increased by 200% pcp4.

¹ 2020 Double 11 Event Official results in unit sales data from Tmall Global (CBEC) platform, 1 Nov to 11 Nov 2020.

² 2020 Double 11 Event Official results in unit sales data from Tmall (General Trade + CBEC) platform, 1 Nov to 11 Nov 2020.

³ 2020 Double 11 Event Official results in unit sales data from Kaola (CBEC) platform, 1 Nov to 11 Nov 2020.

^{4 2020} Double 11 Event Official results in unit sales data from JD (CBEC) platform, 1 Nov to 11 Nov 2020.



CAPRILAC® DOUBLE 11 +48% SALES GROWTH pcp¹.

CapriLac® ranked #1 adult goat powder product on Tmall platform (General Trade + CBEC).



- Flagship Store sales achieved +48% growth on Double 11 pcp¹.
- Total Alibaba Tmall Global sales growth +60% pcp¹.




¹2020 Double 11, official unit sales data from Alibaba platforms, 21 Oct to 11 Nov 2020.



THREE HORIZONS FOR LONG TERM SUSTAINABLE GROWTH

5-year profitable growth strategy towards \$400m target gross revenue.

efficiency







DISCLAIMER

This investor presentation (Presentation) is dated 23 November 2020 and has been prepared by Bubs Australia Limited (ACN 060 094 742) (Bubs or the Company).

The material in this Presentation is general background information about Bubs' activities current at the date of the Presentation. It has been prepared based on information available to it, including information from third parties, and has not been independently verified nor does it purport to be complete. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information or opinions contained in this Presentation.

This Presentation does not constitute investment or financial product advice (nor taxation, accounting or legal advice) and does not take into account the investment objectives, financial situation or needs of any particular investor. It is not a prospectus, product disclosure statement or other disclosure or offering document under Australian law or any other law. This Presentation is not and should not be considered a recommendation to, or offer or an invitation to acquire shares in Bubs, nor does not and will not form the basis of any contract or commitment for the acquisition of shares. The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions.

This Presentation contains certain 'forward-looking statements'. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Bubs, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Bubs' business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Bubs, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to Bubs as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), none of Bubs, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Certain non-IFRS financial information has been included to assist in the making appropriate comparisons with prior periods to assess the operating performance of the business. Bubs uses these measures to assess the performance of the business and believes that the information is useful to investors. Non-IRFS information has not been subject to auditor review.

Unless otherwise stated, all dollar values are in Australian dollars (\$ or A\$). A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding.

